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Immediate surgical revascularization is indicated in the profoundly ischemic limb, that is, class IIb
and early class III (see Figure 17) (see C 2.3, Clinical Classification ofAcute Limb Ischemia, p
5142). Catheter embolectomy is also usuallypreferred for emboli to a nonatherosclerotic limb.
Emboli in nonatherosclerotic limbs usually result in profound ischemia (lIb or III) and therefore are
best treated surgically. In considering operative versus percutaneous revascularization, it must be rec-
ognized that the time from the decision to operate until reperfusion may be substantially longer than
anticipated because of factors outside of the surgeons' control (eg, operating theater availability, anes-
thesia preparation, technical details of the operation).
Recommendation 60: Indications for sw.:gery in acute limb ischemia
Immediately limb-threatening ischemia (class lIb and early class ill) is preferentially
treated surgically.
C 4.3.2 Surgical Technique
Emboli are preferentially removed surgically if they are lodged proximally in the limb or if there is
reason to suspect that they have impacted on a nonatherosclerotic limb. When no further clot can
be retrieved, an angiogram or angioscopy should be performed to visualize distal vessels. In up to
one third of cases, there is residual thrombus, I which, because of the continuing occlusion of the
run-off vessels, can lead to failure.2,3 Some form of intraoperative monitoring of the adequacy of
clot removal is required. The most common of these is "completion" angiography performed
before arteriotomy closure. Fiberoptic endoscopy also has been advocated for this purpose but is
probably inadequate for distal artery visualization.
Distal clot may be treated by intraoperative thrombolysis with instillation of high doses of
thrombolytic agents for a brief period followed by irrigation or additional passages of the bal-
loon catheter. Repeat angiography followed by clinical and Doppler examination of the patient
should be performed on the operating table. This will determine whether the procedure has
been adequate or whether additional attempts at distal clot removal or even bypass are needed.
Percutaneous clot aspiration or thrombolysis, at a later point when the risk of hemorrhage is
reduced, also has been recommended. It is important to continue efforts until there is reason-
able assurance of a viable extremity. As a last resort, isolated limb perfusion technique has been
advocated to reduce the systemic effects of thrombolysis.vf
Unlike embolism, in arterial thrombosis, an underlying local lesion must be sought after clot
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extraction, in addition to residual thrombus. Often this may be suspected from the tactile sensa-
tions and need for deflation at points during the withdrawal of the inflated balloon catheter.
Here completion angiography will help decide between proceeding with a bypass or PTA.
Fortunately, arterial thrombosis superimposed on an already narrowed artery will ordinarily
cause a less severe degree of ischemia because of predevcloped collaterals. Under these circum-
stances, patients may not be operated on initially but will undergo catheter-directed lytic therapy.
Reconunendation 61: Perioperative angiography
Unless there is good evidence that adequate circulation has been restored, eg, bounding
pulses, reactive hyperemia, or excellent distal Doppler signals, intraoperative angiography
should be performed to identify any residual occlusion or critical arteria1lesions requir-
ing further treatment. Imaging should be repeated so that complete clot clearance can be
demonstrated.
Results of Surgical and Endovascular Procedures for Acute Limb Ischemia
Catheter-directed thrombolysis (CDT) has become a commonly employed technique in the
treatment ofALL In the first randomized, controlled small study ofsurgery versus thrombolysis
in patients with ALI (of duration between 24 hours and 14 days), the I-mcnrh limb salvage
rates were 87% and 90% for surgery and thrombolysis, respectively- Secondary procedures were,
however, required in a considerable number of cases. Between 1994 and 1996, three large,
prospective, randomized trials were reported that focused on the comparison of eDT and surgi-
cal revascularization (SR) for treatment of acute limb ischemia.6,7,8 Other studies have been
reported but are not considered here because in some cases there was a lack of prospective ran-
domization, selection bias, or case exclusions,9,lO,1l,12,13,14,15
Limb salvage and mortality rates are recognized as the most important outcome, and the I-year
data are summarized in Table 36. Comparison of these studies is limited by certain differences
in protocol and case mix (eg, acute vs subacute or chronic limb ischemia; thrombotic vs embolic
occlusion; native vs bypass graft occlusion; proximal vs distal occlusions). End points in each of
the studies also vary: the Rochester study used "event-free survival"; the STILE trial used
"composite clinical outcome"; and the TOPAS study used "arterial recanalization and extent of
lysis.II Only the Rochester trial showed any advantage for CDT by primary end points. The
STILE trial favored surgery, and the TaPAS study showed no difference. Other advantages for
CDT could only be shown by post hoc subgroup analysis. Moreover, none of the three pub-
lished reports contain follow-up data regarding those patients treated concurrently at the partic-
ipating institutions but not enrolled in the three studies; such data would help to determine the
extent to which patients who might have been considered appropriate candidates for the respec-
tive therapies were not randomized.
In the Rochester study, patients with class II limb-threatening ischemia ofless than 7 days'
duration were randomly assigned to either CDT with urokinase or SR.6 This included patients
with both thrombotic and embolic occlusions of native arteries and bypass grafts. Any anatomic
lesions were subsequently treated with balloon angioplasty or surgery, but predominantly the
Table 36: Comparison of catheter-directed thrombolysis (eDT) and surgical revascularization (SR) in
treatment of limb ischemia
Results fit
_Cathete.~·_~Dil'ect~dThrombolysis ceDT)
Patients Limb salplIge Martality
(%) (%)
_8~rgiCflI ~~ns.c~a~:i:.ati~ (~J!.)_


























8156 C4 Treatment for Acute Limb Ischemia
JOURNAL OF VASCULAR SURGERY
[anua ry 2000
latter. Although the cumulative limb salvage rates were identical in both groups (82%), the 12-
month mortality rates were markedly higher in the surgical group (42% vs 16%, p = 0.01). This
was primarily as a result of the increased frequency of in-hospital cardiopulmonary complica-
tions in the surgery group (49% vs 16%, p = 0 .001) . This study indicated a clear survival advan-
tage of thrombolytic therapy in the characteristically high-risk patients treated acutely during an
episode of truly limb-threatening ischemia .
The STILE trial enrolled patients with thrombotic native artery or bypass graft occlusions of less
than 6 months' duration? Unfortunately, close to three quarters of these patients had ischemia
of over 14 days' duration, and, importantly, the number with class II limb-threatening ischemia
was negligible. According to prestudy statistical analysis, the trial was originally designed to
include a total of 1,000 patients. However, the interim analysis showed a highly significant differ-
ence at 1 month in the rate of ongoing/recurrent ischemia (54.0% vs 25.7%, p < 0.001) and the
composite clinical outcome (61.7% vs 36 .1%, P < 0.001) in the thrombolytic group compared
with the surgical group. The trial was therefore terminated prematurely. A critical feature of this
and the other trials was the higher-than-anticipated incidence offailure to successfully traverse the
occlusion with a guidewire (28% of patients), obviating lytic therapy. These patients were then
considered treatment failures on an intention-to-treat basis. Whether these strictly monitored trial
data are closer to the truth than clinical reports have suggested has been debated.
The disappointing overall results have led to the STILE data often being presented without the
higher rates of ongoing or recurrent ischemia and major complications for thrombolysis and with
posrrandomization stratification into "before" and "after" 14 days of ischemia. The cut-off of 14
days is arbitrary (and probably unrealistic) in discussing the outcome of "acute" limb ischemia .
The results of thrombolysis are not statistically different between the two periods (although the
results of surgery performed sooner than 14 days being much worse than when it is performed
after more than 14 days improves the comparison in favor of thrombolysis for the early period).
Nevertheless, the early period presents a more reasonable view of thrombolysis in the acute setting.
In the trials discussed here, very few patients enrolled had acute limb ischemia category II or
greater as defined in Recommendation 45 and Recommendation 47. The frequent citing of
these references in discussions on ALI has lead to a review of the results as follows (accepting
that they may apply to only a small subset of patients with ALI): patients with less than 14 days'
duration of ischemia had fewer deaths or amputations combined at 6 months in the eDT group
compared with the SR group (15.3%vs 37.5%, p = 0.01). Even with this finding , the combined
clinical outcome favored surgery. This trend was reversed in the group of patients presenting
with t'chronic" symptoms (>14 days' duration), although the difference was not statistically sig-
nificant (17.8% vs 9.9%, P = 0.08). Subgroup analysis diklosed that, among patients with native
artery occlusions (at 30 days), those treated with eDT had a greater incidence of
ongoing/recurrent ischemia (54.7% vs 23 .5%, P < 0.001) and a worse limb salvage rate (4.1% vs
2.0% major amputation, p = 0.364) compared with the surgical group. Weaver et al carried out
a further subgroup analysis of STILE patients with native artery occlusions . In patients with less
than 14 days' duration of ischemia, at 1 year by intent-to-treat, the mortality rate was less in the
eDT group (6.3%vs. 18.8%, NS) , but the amputation rate was higher compared with surgery
(6.3% vs 0%, NS). The persisting/recurrent ischemia and major complications were higher for
thrombolysis . Thus, in the STILE trials, there seems to be a trade-off between mortality and
amputation and persistent/recurrent ischemia, and major morbidity (Table 37) .
The TOPAS trial investigated patients with limb ischemia of less than 14 days' duration caused
by embolic and thrombotic native artery and bypass graft occlusions. The phase I report empha-
sized the comparison of three different dosages (2,000 IU/min, 4,000 IU/min, 6,000
IV/min) of recombinant urokinase. Primary end points were recanalization and extent of clot
lysis on the arteriogram 4 hours after the infusion. There was no significant difference among
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Table 37: Summary of major findings of the retrospective analysis" of the STILE trial data7,16
Time bId point Sllrgery (%) CDT(%) P
Data group
All patients 1 mo Composite clinical outcome 36.1 61.7 <;0,001
(morbidity, recurrent ischemia,
complications)
All patients 1 mo Ongoing/recurrent ischemia 25.7 54.0 &001
Subgroup analysis
All vessels d 4 days 6 mo Death, amputation 37.5 15.3 0.01
All vessels> 14 days 6 mo Death, amputation 9.9 17.8 0.08
Native artery d4 days 12 mo Mortality 18.8 6.3 NS
Native artery d4 days 12 mo Major amputation 0 6.3 NS
Native artery (all duration) 1 mo Ongoing/recurrent ischemia 23.5 54.7 <;0.001
Native artery (all duration) 1 mo Major amputation 2.0 4.1 0.364
"Intent-to-treat analysis. 28% technical failure (failure to traverse occlusion) with CDT.
the three urokinase dosages in achieving recanalization. The dose of 4,000 IU/min urokinase
was shown to be the safest, with the lowest incidence of hemorrhagic events.
Comparison of CDT for the different urokinase dosages showed no significant difference in
amputation-free survival rates and no advantage over surgery. The actual procedure performed
was less extensive than predicted in 49.7% of CDT patients as compared with 13.8% ofSR
patients. However, in the procedure severity scale used, thrombectomy or PTA were considered
lesser procedures than digital or transmetatarsal amputation. Thrombectomy with
revision/repair of an existing bypass graft was considered a lesser procedure than placement ofa
new bypass. A subsequent analysis of the TaPAS trial determined which patient factors predict-
ed successful therapy in terms of amputation-free survival. Of 28 variables, eight were found to
be predictive using a Cox proportional hazards multifactor analysis. None of these eight favored
one form of treatment over another. The length of occlusion, however, predicted whether a
patient would fare better with thrombolysis or surgery, with occlusions shorter than 30 ern
doing better with surgery and those longer than 30 em doing better with CDT,l7
The only statistically significant overall survival benefit of CDT was found in the Rochester trial
and was related primarily to patients with cardiac disease.s These findings were interpreted to
suggest that CDT may be safer for such patients and can achieve equivalent limb salvage. The
magnitude of the surgical procedure was reduced in approximately 50% of patients in whom
CDT constituted initial therapy even though treatment of underlying lesions was predominantly
surgical. The type of agent used-urokinase, recombinant urokinase, or recombinant tissue plas-
minogen activator-was not shown in the various trials to playa role in determining the results
of CDT. Bleeding complications in patients treated with eDT occurred in 5% to 20% of
patients, but in most this was categorized as minor. No predictors of major bleeding could be
identified by patient characteristics, although a fibrinogen level less than 150 mg/dl, increased
the likelihood of major bleeding.
A meta-analysis reviewing two of these trials has shown an advantage in limb salvage and mor-
tality for catheter-directed thrombolysis.lf Reviewing the data from the few randomized,
prospective studies in ALI, CDT may be viewed as offering advantages when compared with
surgical revascularization in terms of reduced mortality rates and complexity of the surgical pro-
cedure required in exchange for a higher rate of failure to avoid persistent or recurrent ischemia,
major complications, and ultimate risk of amputation. In addition, it appears that reperfusion
with CDT is achieved at a lower pressure and may reduce the risk of reperfusion injury.18 Thus,
if the limb is not immediately or irreversibly threatened, eDT offers a lower-risk opportunity
for arterial revascularization.l? Using this approach, the underlying lesions can be further
defined by angiography, and the appropriate percutaneous or surgical revascularization procc-
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dure can be performed. Therefore, it seems reasonable to recommend eDT as initial therapy in
these particular settings, to be potentially followed by surgical revascularization as needed (see
Recommendation 57, p SI51).
Critical Issue 22: Comparison of therapeutic QptiQns fQr acute limb ischemia
There is a need for prospective, randomized trials to r'igorously compare catheter-direct-
ed thrombolysis (CDT), percutaneous mechanical thrombectomy (PMT), percutaneous
aspiration thromboembolectomy (PAT), intraoperative thrombolysis, and surgical revas-
cularization (SR) for the treatment of thrombotic versus embolic occlusions of native
arteries versus bypass grafts, and that are specifically designed to include determination
of cost-effectiveness and long-term outcome, including functional status.
Critical Issue 23: Further factQrs when cQnsiderin& choice Qf treatment fQr acute limb
ischemia
There is a need, when considering choice of treatment for acute limb ischemia, for fur-
ther studies to obtain additional information concerning:
• the length of time that the lower extremity will tolerate profound ischemia without
permanent damage
• The effect of the duration of the occlusion on the success of recanalization
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C 4.5 Immediate Postprocedural Issues
C 4.5.1 Reperfusion Injury
Reperfusion injury is one of the most common complications leading to prolonged morbidity.
The sudden return of oxygenated blood to acutely ischemic muscle causes the generation and
release of oxygen free radicals and subsequent cellular injury. Failure to anticipate or recognize
this complication can lead to the rapid development of compartment syndrome and myonecrosis.
Treatment consists of fasciotomy. Prevention of reperfusion injury is the focus of much experi-
mental research, but effective drug regimens have not been established for clinicalpractice.
Other long-term complications include the persistence of sensory or motor impairment. Loss of
sensation in the toes and foot increases the likelihood ofdevelopment of neurotrophic ulceration.
Such ulcers are more common in the setting of impaired motor function, A polyneuropathy is
the most common form of residual nerve impairment, although selective damage to individual
nerves has been reported. The manifestations of nerve damage include wasting of the small mus-
cles of the foot associated with painful dysesthesias, leading to an alteration in gait. Treatment
consists of attempts at pharmacological control of pain, bracing of the foot, and physicaltherapy
until neuromotor function improves. This may require many months of intensive therapy.
C 4.5.2 Fasciotomy
Although fasciotomy in every case would produce unacceptable and unnecessary morbidity, in
practice it is often left too late. Compartment pressure measures have been employed to some
advantage, but there is disagreement on pressure criteria for proceeding with fasciotomy. After
revascularization, fasciotomy also should be performed if there are signs of increased ischemia
without evidence of reocclusion. A long skin incision and opening of all compartments, includ-
ing the deep posterior compartment, are needed unless initial inspection shows no muscle death
or swelling.
Recommendation 62: FasciotQrny in acute limb ischemia
Fasciotomy should be performed at the primary procedure if the acute severe ischemia
has been prolonged or if signs of increased compartment pressure develop. This applies
irrespective of how the clot was removed.
C4.6
Critical Issue 24: Predicting the requirement for fasciotomy
There is a need for an easy and accurate test to predict which patients require a fasciotomy.
Treatment of the Underlying Lesion
Simply removing the occluding lesion, whether it is a thrombus or an embolus, is unlikely to be
successful as the sale treatment. If the occlusion was caused by all embolus, the source has to be
identified and treated. If the acute occlusion was caused by thrombosis superimposed on preex-
isting atherosclerosis, then this underlying lesion also has to be treated to avoid a recurrence of
the acute occlusion. This may be accomplished by either an endovascular or and open surgical
technique, depending on the balance between durable success and procedural risk. The results
of PTA in the literature are dependent on morphology of the lesion and patient selection and
the criteria used to define technical and clinical success and patency. These are well discussed in
sections B 4.3, Endovascular Procedures for Intermittent Claudication (p 597), D 4.6,
Aortoiliac Discase-Endovascular Treatment (p 5214), D 4.9, Infrainguinal Lesions-
